Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights
  • Choose License Type

The Global Sciatica Market, by Disease Type (Acute Sciatica, Chronic Sciatica, and Others), by Drug Class (Nonsteroidal Anti-Inflammatory Drugs, Oral Steroids, Anticonvulsant Agents, Tricyclic Antidepressants, Opioid Analgesics, and Others), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America)  was valued at US$ 6,302.9 Million in 2021 and is projected to exhibit a CAGR of 4.8% during the forecast period (2021-2028).

The key market players are focusing on the introduction of novel medicines for the treatment of sciatica, which is projected to provide a profitable opportunity for industry participants to introduce their novel products. For instance, in November 2018, Sollis Therapeutics, Inc., an Ohio-based interventional pain therapeutics company, announced that the first patient in the RePRIEVE-CM trial, a Phase III clinical trial conducted to evaluate the safety and efficacy of the extended release non-opioid, non-steroid clonidine micropellet for the treatment of sciatica pain, has been enrolled.

Global Sciatica Market – Impact of Coronavirus (COVID-19) Pandemic

COVID-19 pandemic has affected various industries globally. The players operating in the global sciatica market are facing major challenges on various fronts due to the COVID-19 pandemic. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, the number of COVID-19 cases reported globally, as of August 4, 2021, are approximately 199,466,211 confirmed cases with 4,180,161 deaths.

The Coronavirus pandemic has negatively impacted the development, production, and supply of pharmaceutical products and affected growth of the medication used in treatment of sciatica such as non-steroidal anti-inflammatory drugs (NSAIDS), oral analgesics, and others manufactured by various companies across the regions such as North America, Europe, and Asia Pacific. Moreover, the supply and production of pharmaceutical products is also affected due to COVID-19 pandemic lockdown imposed globally. This lockdown has resulted in closure of industrial establishments, except manufacturing of essential commodities, and disruption in supply chain of the pharmaceutical products.

Browse 44 Market Data Tables and 37 Figures spread through 237 Pages and in-depth TOC on “ Global Sciatica market”-  Forecast to 2028,  Global Sciatica market, by Disease Type (Acute Sciatica, Chronic Sciatica, and Others), by Drug Class (Nonsteroidal Anti-Inflammatory Drugs, Oral Steroids, Anticonvulsant Agents, Tricyclic Antidepressants, Opioid Analgesics, and Others), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America)

To know the latest trends and insights prevalent in the Sciatica Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/sciatica-market-4607

The increasing prevalence of sciatica is anticipated to drive the growth of global sciatica market over the forecast period. For instance, according to the article published in the National Centre for Biotechnology Information in June 2021, sciatica has some unique epidemiologic characteristics including, no gender predominance, peak incidence take place in patients in their fourth decade, lifetime occurrence reported between 10% to 40%, an annual incidence rate of sciatica is 1% to 5% globally, and it rarely occurs before age 20 unless the patient has trauma.

Key Takeaways of the global Sciatica market:

  • The global sciatica market is expected to exhibit a CAGR of 4.8% during the forecast period, owing to increasing research and development activities by the key players for the development and launch of novel therapeutics for the treatment of sciatica. For instance, on May 30, 2018, Seikagaku Corporation, a pharmaceutical company, initiated a phase III A Multicenter, Randomized, Double-blind, Shamcontrolled, Comparative Study of SI-6603 in Subjects with Lumbar Disc Herniation. The study is estimated to complete by November 2022.
  • Among disease type, acute sciatica segment is expected to lead the global sciatica market owing to its high incidence. For instance, according to the African Journal of Pharmacy and Pharmacology report ‘Sciatica: Medical treatment or Physiotherapy’ in 2019, stated that in 2017 there were approximately 20% of individuals suffered from acute sciatic in Pakistan.
  • Among drug class, nonsteroidal anti-inflammatory drugs segment is estimated to account for 44.8% market share in 2021 owing to increasing product approval. For instance, in July 2018, Aurobindo Pharma Ltd. received final approval from the U.S. Food and Drug Administration to manufacture and market Ibuprofen capsules, used to relieve pain and reduce fever.
  • Major players operating in the global sciatica market include Sorrento Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Jubilant Life Sciences Ltd., Hikma Pharmaceuticals PLC., Mylan N.V., Horizon Therapeutics Plc., Sun Pharmaceutical Industries Ltd., Alkem Labs, SCILEX Pharmaceuticals, Inc., Seikagaku Corporation, Kolon Life Science, Inc., Teijin Limited, and SpineThera, Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.